Clinical Trials: Clinical Trials in USA

FDA IND Submission Process: A Complete Sponsor Guide for U.S. Clinical Trials

Posted on digi By digi

Sponsors should: (1) engage FDA early with focused questions; (2) run cross-functional “readiness sprints” to reconcile nonclinical, clinical, and CMC narratives; (3) simulate dose-escalation operating characteristics; (4) validate decentralized and digital elements (audit trails, privacy, device performance); (5) stress-test safety reporting against 21 CFR 312.32 decision trees; (6) maintain flawless forms (1571/1572/3674) and financial disclosures; (7) pilot the eCTD backbone with hyperlinks and lifecycle controls; (8) conduct mock quality reviews of the IB and protocol; (9) prepare an inspection binder for Phase 1 units; (10) document every major assumption in the TPP and SAP.

Click to read the full article.

Clinical Trials in USA, Country-Specific Clinical Trials

Institutional Review Boards (IRBs) in U.S. Clinical Trials: Roles, Regulations, and Best Practices

Posted on digi By digi

Sponsors and investigators should build IRB collaboration into trial planning: use standardized consent templates, budget realistic timelines for review cycles, align recruitment materials early, and establish strong communication with IRB coordinators. For multi-site trials, reliance agreements should be drafted early. IRBs should invest in training, adopt electronic systems, and periodically audit their procedures to ensure readiness for FDA inspection.

Click to read the full article.

Clinical Trials in USA, Country-Specific Clinical Trials

Decentralized Clinical Trials in the United States: Regulatory Acceptance and Best Practices

Posted on digi By digi

Sponsors should pilot decentralized elements before scaling, ensure early IRB engagement, conduct participant usability testing, validate digital endpoints, and implement layered monitoring. Contracts with vendors should clearly define data ownership, privacy obligations, and uptime guarantees. A DCT readiness checklist covering regulatory, technical, operational, and participant engagement dimensions is recommended.

Click to read the full article.

Clinical Trials in USA, Country-Specific Clinical Trials

How HIPAA Impacts Clinical Data Management in U.S. Clinical Trials

Posted on digi By digi

Sponsors should adopt standardized HIPAA authorization templates, conduct site training on PHI handling, and map all data flows to confirm safeguards. Business Associate Agreements with CROs and vendors should be executed before trial start. Data minimization, encryption, role-based access, and regular privacy audits reduce risks. Mock HIPAA audits at sites can identify gaps in advance of FDA or OHRP inspections.

Click to read the full article.

Clinical Trials in USA, Country-Specific Clinical Trials

Oncology Clinical Trial Trends in the United States: Innovation, Regulation, and Future Outlook

Posted on digi By digi

Oncology sponsors should: (1) integrate biomarker validation early; (2) use master protocols for efficiency; (3) engage FDA via Type C meetings for novel designs; (4) ensure diversity action plans are built into recruitment; (5) validate digital endpoints before inclusion; (6) maintain robust pharmacovigilance systems; (7) prepare for accelerated approval post-marketing obligations; (8) leverage RWD to supplement rare cancer evidence; (9) adopt hybrid operational models; and (10) document all patient-centric approaches in submissions.

Click to read the full article.

Clinical Trials in USA, Country-Specific Clinical Trials

Phase 1 Clinical Pharmacology Studies in the United States: Design, Regulation, and Execution

Posted on digi By digi

Sponsors should conduct readiness reviews covering protocol design, site preparedness, CMC documentation, and regulatory filings. Mock dosing drills, robust escalation governance, and backup safety measures reduce risks. Aligning with FDA through pre-IND meetings ensures acceptance of proposed dose ranges and safety monitoring plans.

Click to read the full article.

Clinical Trials in USA, Country-Specific Clinical Trials

Adaptive Clinical Trial Designs Under FDA Guidelines: Opportunities and Challenges

Posted on digi By digi

Sponsors should: (1) conduct extensive simulations; (2) prespecify adaptation rules; (3) engage FDA early via Type C meetings; (4) establish independent DMCs; (5) validate electronic systems for real-time data; (6) use centralized monitoring; (7) ensure robust governance charters; (8) prepare communication strategies for investigators; (9) document adaptation rationales transparently; and (10) harmonize global submissions with EMA/PMDA to avoid duplication.

Click to read the full article.

Clinical Trials in USA, Country-Specific Clinical Trials

Use of Digital Health Technologies in U.S. Clinical Trials: FDA Perspectives and Practical Insights

Posted on digi By digi

Sponsors should: (1) validate DHTs thoroughly; (2) align endpoints with patient priorities; (3) train participants and staff in device use; (4) implement robust vendor oversight; (5) adopt backup and contingency procedures; (6) address diversity and accessibility barriers; (7) secure IRB approval for digital consent and telemedicine; (8) prepare for FDA inspection of systems; and (9) monitor global regulatory developments. A DHT integration checklist can streamline planning and execution.

Click to read the full article.

Clinical Trials in USA, Country-Specific Clinical Trials

Clinical Trial Site Accreditation in the United States Explained

Posted on digi By digi

Sites should: (1) pursue voluntary accreditation programs such as AAHRPP; (2) implement continuous GCP training; (3) maintain SOPs with version control; (4) conduct regular mock inspections; (5) document all processes thoroughly; (6) engage with IRBs proactively; (7) qualify vendors and maintain oversight; (8) invest in infrastructure upgrades; (9) maintain robust CAPA processes; and (10) align site practices with FDA and ICH expectations.

Click to read the full article.

Clinical Trials in USA, Country-Specific Clinical Trials

Digital Health and eConsent in U.S. Clinical Trials: Regulatory Guidance and Implementation

Posted on digi By digi

To ensure success, sponsors should: (1) validate eConsent platforms for Part 11 compliance; (2) engage IRBs early; (3) provide participant training; (4) qualify vendors rigorously; (5) integrate HIPAA safeguards; (6) adopt contingency plans for system failures; (7) address diversity through device provision and translations; (8) maintain inspection readiness; and (9) document all processes thoroughly in the TMF.

Click to read the full article.

Clinical Trials in USA, Country-Specific Clinical Trials